Austedo Generic Name Deutetrabenazine DrugBank Accession Number DB12161 Background Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) …

Deutetrabenazine, sold under the brand name Austedo, is a vesicular monoamine transporter 2 inhibitor which is used for the treatment of chorea associated with Huntington's disease and …

The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. Adverse …

May 2, 2025 · The mechanism of action of deutetrabenazine is believed to be related to its effect as a reversible depletor of monoamines from nerve terminals. The major circulating …

Deutetrabenazine (Austedo) can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Anyone considering the use of …

Aug 31, 2023 · Description Tetrabenazine (Xenazine), deutetrabenazine (Austedo) and valbenazine (Ingrezza/Ingrezza Sprinkle) are reversible vesicular monoamine transporter 2 …

Mechanism of Action Deutetrabenazine exerts its action after getting metabolized to α-dihydrotetrabenazine (HTBZ) and β-HTBZ, its major metabolites that reversibly inhibit VMAT2, …

Feb 28, 2025 · AUSTEDO XR extended-release tablets and AUSTEDO tablets are formulated with deutetrabenazine, a vesicular monoamine transporter 2 (VMAT2) inhibitor for oral …

Feb 10, 2025 · Deutetrabenazine Mechanism of Action Deuterium-substituted analog of tetrabenazine; deuterium, a nontoxic, naturally occurring isotope of hydrogen with a higher …

Jul 17, 2024 · Deutetrabenazine, also known by its brand name Austedo, is a medication primarily used to treat involuntary movements (chorea) associated with Huntington's disease and …